PT3006040T - Métodos e composições para o tratamento de neuropatias - Google Patents
Métodos e composições para o tratamento de neuropatiasInfo
- Publication number
- PT3006040T PT3006040T PT151930682T PT15193068T PT3006040T PT 3006040 T PT3006040 T PT 3006040T PT 151930682 T PT151930682 T PT 151930682T PT 15193068 T PT15193068 T PT 15193068T PT 3006040 T PT3006040 T PT 3006040T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- methods
- treating neuropathies
- neuropathies
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57723304P | 2004-06-04 | 2004-06-04 | |
US64133005P | 2005-01-04 | 2005-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3006040T true PT3006040T (pt) | 2018-03-28 |
Family
ID=35782237
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT151930682T PT3006040T (pt) | 2004-06-04 | 2005-06-03 | Métodos e composições para o tratamento de neuropatias |
PT57902835T PT1755391E (pt) | 2004-06-04 | 2005-06-03 | Métodos e composições para o tratamento de neuropatias |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT57902835T PT1755391E (pt) | 2004-06-04 | 2005-06-03 | Métodos e composições para o tratamento de neuropatias |
Country Status (10)
Country | Link |
---|---|
US (4) | US7776326B2 (pt) |
EP (2) | EP3006040B1 (pt) |
JP (1) | JP2008501343A (pt) |
CN (1) | CN1964627B (pt) |
AU (1) | AU2005257883A1 (pt) |
CA (1) | CA2567848A1 (pt) |
DK (1) | DK1755391T3 (pt) |
ES (2) | ES2663226T3 (pt) |
PT (2) | PT3006040T (pt) |
WO (1) | WO2006001982A2 (pt) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
CA2548671C (en) | 2003-12-29 | 2015-02-24 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US20050227327A1 (en) * | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
US7776326B2 (en) * | 2004-06-04 | 2010-08-17 | Washington University | Methods and compositions for treating neuropathies |
WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
CN101124012B (zh) * | 2004-12-27 | 2012-09-05 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病的装置 |
US11207518B2 (en) * | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
WO2006076681A2 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
WO2006105440A2 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
US20060270614A1 (en) * | 2005-05-24 | 2006-11-30 | Sekhar Boddupalli | Use of chalcones for the treatment of viral disorders |
US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
JP2008542296A (ja) * | 2005-05-25 | 2008-11-27 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュイン活性化剤による眼障害の処置 |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US7718830B2 (en) | 2006-04-24 | 2010-05-18 | Allergan, Inc. | Abnormal cannabidiols as agents for lowering intraocular pressure |
US7618966B2 (en) | 2006-04-24 | 2009-11-17 | Allergan, Inc. | Abnormal Cannabidiols as agents for lowering intraocular pressure |
BRPI0710732A2 (pt) | 2006-04-24 | 2011-11-08 | Allergan Inc | canabidióis anormais como agentes para redução da pressão intraocular |
US7612101B2 (en) | 2006-04-24 | 2009-11-03 | Allergan, Inc. | Abnormal cannabidiols as agents for lowering intraocular pressure |
AU2007314141A1 (en) * | 2006-10-30 | 2008-05-08 | Novogen Research Pty Ltd | Prevention and reversal of chemotherapy-induced peripheral neuropathy |
MX2009008022A (es) * | 2007-01-26 | 2009-12-11 | Univ Washington | Metodos y composiciones para tratar neuropatias. |
TW200918542A (en) * | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
US20090005324A1 (en) * | 2007-06-29 | 2009-01-01 | Rong-Tsun Wu | Biologically active extract from dendrobium plant, use thereof and process for preparing the same |
US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
US20110082189A1 (en) * | 2007-10-23 | 2011-04-07 | President And Fellows Of Harvard College | Use of compounds activating sirt-3 for mimicking exercise |
EP2259782A4 (en) | 2008-03-03 | 2013-01-23 | Nad Life Pty Ltd | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US8886339B2 (en) | 2009-06-09 | 2014-11-11 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US20110054569A1 (en) * | 2009-09-01 | 2011-03-03 | Zitnik Ralph J | Prescription pad for treatment of inflammatory disorders |
US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
WO2011081945A2 (en) * | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt6 |
EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
KR20110097100A (ko) * | 2010-02-24 | 2011-08-31 | 전북대학교산학협력단 | 프리온 질병의 치료 및 예방에 효과를 갖는 레스베라트롤 |
GB201006961D0 (en) * | 2010-04-27 | 2010-06-09 | Babraham Inst | NMN modulator |
WO2012004917A1 (ja) * | 2010-07-06 | 2012-01-12 | Kaminishi Hidenori | 神経突起伸長剤 |
WO2012007458A1 (en) | 2010-07-12 | 2012-01-19 | Universidad Autónoma De Barcelona | Gene therapy composition for use in diabetes treatment |
IT1406221B1 (it) * | 2010-12-13 | 2014-02-14 | Mkpharma Srl | Composizione contenente resveratrolo l/triptofano acido l/aspartico e vitamina b3 (nad+) per l'impiego in campo farmaceutico nutrizionale e cosmetico |
WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
WO2012141876A1 (en) * | 2011-04-15 | 2012-10-18 | Nestec S.A. | Methods for regulating sirtuin gene expression |
US20120328526A1 (en) * | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
CN103827293A (zh) * | 2011-06-29 | 2014-05-28 | 通用医疗公司 | 用于增强雌性生殖细胞中生物能状态的组合物和方法 |
EP2726477A4 (en) * | 2011-06-29 | 2015-08-26 | Harvard College | SMALL MOLECULAR CD38 HEMMER AND USE METHOD THEREFOR |
EP2574339A1 (de) | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
CN104487575B (zh) * | 2012-07-28 | 2017-09-19 | 深圳华大基因股份有限公司 | Nmnat1突变基因、检测其的引物、试剂盒和方法以及其用途 |
WO2014059031A2 (en) * | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors in the prevention and treatment of inflammation |
US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
CN103054850A (zh) * | 2013-01-08 | 2013-04-24 | 赤峰学院附属医院 | 松属素在制备治疗神经退行性疾病药物中的用途 |
US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
ES2952032T3 (es) | 2013-03-15 | 2023-10-26 | Washington University St Louis | Administración de mononucleótido de nicotinamida en el tratamiento de ojo seco |
US20160354489A1 (en) * | 2013-09-26 | 2016-12-08 | Universitat Autònome de Barcelona | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |
EP3063163B1 (en) | 2013-10-30 | 2022-08-10 | Chromadex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
WO2015070280A1 (en) * | 2013-11-14 | 2015-05-21 | Newsouth Innovations Pty Limited | Senescence and senescence associated secretory phenotype |
WO2015094532A1 (en) * | 2013-12-17 | 2015-06-25 | Mjn U.S. Holdings Llc | Nutritional composition containing a neurologic component of kaempferol and/or fisetin |
US20150297508A1 (en) * | 2014-04-21 | 2015-10-22 | William Andriette | Topical Formulation to Enhance Genital Sensation and Function |
WO2015186114A1 (en) | 2014-06-06 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
PL3670522T3 (pl) | 2014-07-24 | 2022-02-21 | W.R. Grace & Co. - Conn. | Krystaliczna postać chlorku rybozydu nikotynamidu |
CA2960912A1 (en) | 2014-09-16 | 2016-03-24 | Universitat Autonoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
US20160089383A1 (en) * | 2014-09-29 | 2016-03-31 | Everbloom, Llc | Nutritional supplements |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
WO2016086088A2 (en) * | 2014-11-25 | 2016-06-02 | Northwestern University | Wound healing through sirt1 overexpression |
WO2016122832A1 (en) * | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
EP3268379B1 (en) | 2015-03-09 | 2023-11-01 | W.R. Grace & CO. - CONN. | Crystalline form of nicotinamide riboside |
BR112017019696A2 (pt) | 2015-03-16 | 2018-09-04 | ChromaDex Inc. | composto e usos de um composto |
CN104758307A (zh) * | 2015-03-16 | 2015-07-08 | 邦泰生物工程(深圳)有限公司 | Nadh和nmn在制备帕金森病药物或保健品的应用 |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
JP6545256B2 (ja) * | 2015-03-31 | 2019-07-17 | 新興和製薬株式会社 | レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物 |
AU2016255853B2 (en) * | 2015-04-28 | 2021-08-05 | Newsouth Innovations Pty Limited | Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity |
US11559421B2 (en) | 2015-06-25 | 2023-01-24 | Hill-Rom Services, Inc. | Protective dressing with reusable phase-change material cooling insert |
WO2016210232A1 (en) * | 2015-06-25 | 2016-12-29 | N.V. Perricone Llc | Niacinamide mononucleotide formulations for skin aging |
BR112018002168B1 (pt) | 2015-08-05 | 2023-10-10 | Metro International Biotech, Llc | Composto, ou um estereoisômero ou sal do mesmo, uso do composto e composição que compreende um composto ou um sal farmaceuticamente aceitável do mesmo |
JP6165380B1 (ja) * | 2015-08-18 | 2017-07-19 | レジリオ株式会社 | 神経回路網の再構築・賦活剤 |
GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
KR20180066229A (ko) * | 2015-10-23 | 2018-06-18 | 더 잭슨 래보라토리 | 안구 신경변성 장애(예, 녹내장)의 치료 및 예방에 사용되는 니코틴아미드 |
CN106659729A (zh) * | 2015-12-11 | 2017-05-10 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 |
WO2016188092A1 (zh) * | 2015-12-11 | 2016-12-01 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的保健品中的应用及其保健品 |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11103496B2 (en) | 2016-02-22 | 2021-08-31 | The Trustees Of The University Of Pennsylvania | Methods for enhancing liver regeneration |
MX2018012527A (es) * | 2016-04-14 | 2019-08-21 | Chromadex Inc | Uso de ribosido de nicotinamida, ribosido de acido nicotinico, mononucleotido de nicotinamida y derivados de compuestos nicotinoílo en formula para lactantes. |
CA3021571C (en) | 2016-04-20 | 2023-01-03 | ChromaDex Inc. | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors |
EP3472176A4 (en) * | 2016-06-21 | 2020-02-26 | Sphaera Pharma Pvt. Ltd. | THE USEFULNESS OF (+) EPICATECHIN AND THEIR ANALOGS |
JP7090336B2 (ja) * | 2016-08-08 | 2022-06-24 | 慶應義塾 | Nad関連代謝産物の利用 |
EP3500267A4 (en) * | 2016-08-22 | 2020-03-18 | Elysium Health, Inc. | NICOTINAMIDE RIBOSIDE AND PTEROSTILBENE COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS |
WO2018052019A1 (ja) * | 2016-09-13 | 2018-03-22 | めぐみ 田中 | 視覚機能改善剤及び視覚機能の改善方法 |
AU2017356475B2 (en) | 2016-11-11 | 2023-11-30 | ChromaDex Inc. | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
US11633421B2 (en) | 2016-11-29 | 2023-04-25 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
CN110325190A (zh) * | 2016-12-21 | 2019-10-11 | 新南创新私人有限公司 | 增加血管密度的方法 |
EP3634986A4 (en) * | 2017-04-24 | 2021-09-08 | The Trustees of The University of Pennsylvania | GENE THERAPY FOR EYE DISEASES |
TW201919647A (zh) | 2017-08-10 | 2019-06-01 | 華盛頓大學 | 使用菸鹼醯胺單核苷酸之組成物及治療方法 |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
JP7072825B2 (ja) * | 2017-09-13 | 2022-05-23 | 三菱電機ソフトウエア株式会社 | コピー数計測装置、コピー数計測プログラムおよびコピー数計測方法 |
EP3682746A4 (en) * | 2017-09-14 | 2021-03-10 | Megumi Tanaka | AGING PROTECTION AGENTS AND AGING PROTECTION PROCEDURES |
US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
CA3086535A1 (en) | 2017-12-22 | 2019-06-27 | Elysium Health, Inc. | Crystalline forms of nicotinamide riboside chloride |
AU2019214858B2 (en) | 2018-01-30 | 2023-02-02 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
CN112739222A (zh) * | 2018-09-14 | 2021-04-30 | 田中惠 | 抗衰老剂以及抗衰老方法 |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US20220072019A1 (en) * | 2018-10-19 | 2022-03-10 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
CN109925308A (zh) * | 2018-12-29 | 2019-06-25 | 广东宏盈科技有限公司 | 异黄酮在制备治疗眼底黄斑病变的药物中的应用 |
US20220160688A1 (en) * | 2019-03-20 | 2022-05-26 | The Johns Hopkins University | Inhibition of nampt and/or sarm1 for the treatment of axonal degradation |
US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
JP2022541058A (ja) | 2019-07-19 | 2022-09-21 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
CN110507695A (zh) * | 2019-08-20 | 2019-11-29 | 泓博元生命科技(深圳)有限公司 | Nadh和/或nmn在制备脑功能恢复的药物、保健品中的应用 |
CN113117083A (zh) * | 2019-12-31 | 2021-07-16 | 刘永政 | 提升哺乳动物Sirtuin蛋白家族活性的物质的应用 |
FR3106056B1 (fr) * | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
MX2022011177A (es) * | 2020-03-11 | 2022-12-13 | Massachusetts Eye & Ear Infirmary | Terapia genica para la degeneracion de la retina asociada a nmnat1. |
KR20220154210A (ko) * | 2020-03-16 | 2022-11-21 | 메구미 타나카 | 코엔자임 q(coenzyme q) 생산 촉진제 및 코엔자임 q 생산 촉진 방법 |
EP4153053A1 (en) | 2020-05-21 | 2023-03-29 | The Feinstein Institutes for Medical Research | Systems and methods for vagus nerve stimulation |
CN112245446A (zh) * | 2020-10-20 | 2021-01-22 | 合肥康诺生物制药有限公司 | Nad在制备治疗阿尔兹海默症药物中的用途 |
EP4196127B1 (en) * | 2020-12-18 | 2024-01-31 | Nuvamid SA | Nicotinamide mononucleotide derivatives in the treatment and prevention of sickle cell disease |
CN112675152A (zh) * | 2020-12-25 | 2021-04-20 | 厦门金达威生物科技有限公司 | 一种nmn缓释肠溶性微胶囊及其制备方法 |
EP4346842A1 (en) | 2021-05-27 | 2024-04-10 | Metro International Biotech, LLC | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
JP2023005922A (ja) * | 2021-06-29 | 2023-01-18 | 株式会社常磐植物化学研究所 | サーチュイン活性化剤 |
CN114045288A (zh) * | 2021-10-21 | 2022-02-15 | 浙江大学 | 靶向敲降SIRT2基因的shRNA及烟酰胺腺嘌呤二核苷酸的前体在制备治疗神经退行性疾病的药物中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
DE69603613T2 (de) * | 1995-09-08 | 2000-03-02 | Sanofi Synthelabo | 4-(cycloalkyl)piperidine und 4-(cycloalkylalkyl)-piperidine, ihre herstellung und therapeutische verwendung |
TR200001149T2 (tr) * | 1997-10-28 | 2000-08-21 | Unilever N.V. | Oda sıcaklığında niteliği bozulmayan niteliği bozulmayan ve esası çay olan bir içecek |
CA2326600A1 (en) | 1998-04-28 | 1999-11-04 | Mitokor | Cellular and animal models for diseases associated with altered mitochondrial function |
EP1181374A4 (en) | 1999-05-28 | 2003-04-23 | Immunex Corp | NEW HUMAN AND MURINE KINASES |
US6573299B1 (en) | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
CN1270034A (zh) | 1999-11-04 | 2000-10-18 | 第一军医大学珠江医院 | 辅酶在组织细胞化学和辐射损伤防治中的应用 |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
FR2842424A1 (fr) * | 2002-07-22 | 2004-01-23 | Univ Paris 7 Denis Diderot | Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
CA2421269A1 (en) * | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
AU2004253579B2 (en) | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
WO2005004814A2 (en) * | 2003-07-02 | 2005-01-20 | Elixir Pharmaceuticals, Inc. | Sirt1 and genetic disorders |
EP1723227A4 (en) * | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
US20050227327A1 (en) * | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
US7776326B2 (en) * | 2004-06-04 | 2010-08-17 | Washington University | Methods and compositions for treating neuropathies |
JP2008528510A (ja) * | 2005-01-20 | 2008-07-31 | サートリス ファーマシューティカルズ, インコーポレイテッド | 紅潮および/または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用 |
WO2007019346A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
-
2005
- 2005-06-03 US US11/144,358 patent/US7776326B2/en active Active
- 2005-06-03 AU AU2005257883A patent/AU2005257883A1/en not_active Abandoned
- 2005-06-03 WO PCT/US2005/019524 patent/WO2006001982A2/en not_active Application Discontinuation
- 2005-06-03 ES ES15193068.2T patent/ES2663226T3/es active Active
- 2005-06-03 EP EP15193068.2A patent/EP3006040B1/en active Active
- 2005-06-03 DK DK05790283.5T patent/DK1755391T3/en active
- 2005-06-03 CA CA002567848A patent/CA2567848A1/en not_active Abandoned
- 2005-06-03 PT PT151930682T patent/PT3006040T/pt unknown
- 2005-06-03 ES ES05790283.5T patent/ES2557810T3/es active Active
- 2005-06-03 EP EP05790283.5A patent/EP1755391B1/en active Active
- 2005-06-03 PT PT57902835T patent/PT1755391E/pt unknown
- 2005-06-03 CN CN2005800181148A patent/CN1964627B/zh active Active
- 2005-06-03 JP JP2007515603A patent/JP2008501343A/ja active Pending
-
2010
- 2010-05-28 US US12/790,722 patent/US8889126B2/en active Active
-
2014
- 2014-10-10 US US14/511,701 patent/US9295688B2/en active Active
-
2016
- 2016-03-11 US US15/067,449 patent/US20160199401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2557810T3 (es) | 2016-01-28 |
US7776326B2 (en) | 2010-08-17 |
US20160199401A1 (en) | 2016-07-14 |
EP1755391A4 (en) | 2010-03-10 |
US20100272702A1 (en) | 2010-10-28 |
CN1964627A (zh) | 2007-05-16 |
DK1755391T3 (en) | 2016-02-08 |
EP3006040B1 (en) | 2017-11-22 |
US9295688B2 (en) | 2016-03-29 |
AU2005257883A1 (en) | 2006-01-05 |
CA2567848A1 (en) | 2006-01-05 |
JP2008501343A (ja) | 2008-01-24 |
EP1755391A2 (en) | 2007-02-28 |
EP1755391B1 (en) | 2015-11-11 |
US8889126B2 (en) | 2014-11-18 |
EP3006040A1 (en) | 2016-04-13 |
PT1755391E (pt) | 2016-02-03 |
CN1964627B (zh) | 2011-10-19 |
ES2663226T3 (es) | 2018-04-11 |
US20150038560A1 (en) | 2015-02-05 |
WO2006001982A2 (en) | 2006-01-05 |
WO2006001982A3 (en) | 2006-08-17 |
US20060002914A1 (en) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1755391E (pt) | Métodos e composições para o tratamento de neuropatias | |
HK1216080A1 (zh) | 用於治療或預防草酸鹽相關疾病的組合物和方法 | |
HK1121952A1 (en) | Methods and compositions for treating conditions | |
GB2423928B (en) | Methods and compositions for treating pain | |
EP1737482A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
IL180844A0 (en) | Compositions and methods for treating excessive bleeding | |
IL184047A0 (en) | Methods and compositions for treating amyloid-related diseases | |
EP1732650A4 (en) | COMPOSITION AND METHOD FOR CANCER TREATMENT | |
EP1959929A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING | |
IL176919A0 (en) | Methods and compositions for treating cancer | |
IL176259A0 (en) | Compositions and methods for treating diabetes | |
IL186963A0 (en) | Methods and compositions for treating pain | |
IL185056A0 (en) | Compositions and methods for treating or preventing flaviviridae infections | |
EP2124985A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS | |
EP1890712A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN | |
EP1940437A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF BACTERIA | |
ZA200708575B (en) | Methods and compositions for treating or preventing cancer | |
EP1755537A4 (en) | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA | |
ZA200608932B (en) | Method and compositions for epilation | |
EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
IL184062A0 (en) | Visco-supplement composition and methods | |
ZA200605722B (en) | Composition and method | |
ZA200706038B (en) | Visco-supplement composition and methods | |
GB0419175D0 (en) | Method of treatment and compositions | |
EP1796712A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HYPERCHOLESTEROLEMIA |